Move over, oncology: Obesity, diabetes meds will take over 2030's top drug rankings, Evaluate forecasts

It’s well known that obesity drugs from Novo Nordisk and Eli Lilly are on a high-flying growth trajectory that doesn’t look to be letting up anytime soon. But, according to a new report from Evaluate, obesity products are set to take over many familiar stalwarts on the world’s top-selling drugs list by the end of the decade.